One To Watch

Citius Oncology

Company Overview

A commercially-stage oncology biopharmaceutical company whose FDA-approved LYMPHIR (denileukin diftitox-cxdl) is gaining rapid traction in relapsed or refractory cutaneous T-cell lymphoma while investigator-led studies probe expansion into DLBCL and solid tumors. Citius Oncology trades on Nasdaq under the ticker CTOR and is majority-owned (~90%) by Citius Pharmaceuticals following an August 2024 merger with TenX Keane. The company's entire commercial focus rests on LYMPHIR, which launched in the US in December 2025 and generated $5.6 million in net revenue in the first half of fiscal 2026 at approximately 80% gross margin.

Headquarters and Global Presence

Citius Oncology is headquartered in Cranford, New Jersey, and operates under a shared services agreement with parent company Citius Pharmaceuticals. European distribution is handled through a regional partnership with Uniphar, which received its first LYMPHIR shipment on April 29, 2026.

Founding and History

Citius Oncology emerged as a standalone Nasdaq-listed entity in August 2024 following the merger of Citius Pharmaceuticals' oncology assets with TenX Keane, a special purpose acquisition vehicle. Leonard L. Mazur, who had led the oncology program within Citius Pharma, assumed the role of Chairman, CEO, and President at formation. The company secured FDA approval for LYMPHIR and executed a US commercial launch in December 2025, marking its transition from development-stage to revenue-generating business.

Therapy Areas and Focus

Citius Oncology is focused on hematologic malignancies and, through expansion studies, solid tumors. Its anchor indication — relapsed or refractory CTCL — is a rare, chronic skin lymphoma with limited approved options and high unmet need in later lines of therapy. Investigator-sponsored programs are testing LYMPHIR's utility as a lymphodepletion agent ahead of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma, and in combination with checkpoint inhibition in solid tumors — two directions that, if they generate controlled trial data, could substantially expand the addressable market.

Technology Platforms and Modalities

LYMPHIR is a recombinant fusion protein that combines human interleukin-2 (IL-2) with a truncated diphtheria toxin, directing cytotoxic killing selectively to cells expressing the high-affinity IL-2 receptor (CD25). CD25 is overexpressed on malignant T-cells in CTCL, providing the therapeutic rationale for tumor-selective cytotoxicity. The reformulated version (denileukin diftitox-cxdl) uses a proprietary manufacturing process that improves protein stability and purity relative to the original Ontak formulation, an important distinction in a class of agents where tolerability historically limited use. The same CD25-targeting logic underpins the CAR-T preconditioning hypothesis: depleting regulatory T-cells in the tumor microenvironment before adoptive cell therapy could enhance engraftment and efficacy.

Key Pipeline and Programs

LYMPHIR (denileukin diftitox-cxdl) holds FDA approval for adults with relapsed or refractory CTCL and represents the company's sole commercial asset. Beyond the approved indication, an investigator-sponsored study at the University of Minnesota is evaluating LYMPHIR as a lymphodepleting agent prior to CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma; positive topline data from this study were presented at ASTCT 2026. A Phase I study at the University of Pittsburgh Medical Center (UPMC) examined LYMPHIR in combination with pembrolizumab across solid tumor types and reported positive topline results, establishing tolerability for the combination. Together these programs — CTCL (approved), DLBCL pre-CAR-T (investigator-sponsored), and solid tumors plus checkpoint inhibitor (Phase I complete) — define the current clinical scope. No formal Phase II or III expansion trials have been announced by the company itself at this stage; the investigator data will likely shape whether Citius Oncology funds its own controlled expansion studies.

Recent Developments

In March 2026, Citius Oncology reported near-100% payer coverage for LYMPHIR, with 83% of target accounts on formulary or in formulary review — a commercially meaningful milestone for a newly launched rare-disease oncology product. First revenue was reported in H1 fiscal 2026 at $5.6 million net, and the company shipped LYMPHIR to Europe via Uniphar for the first time on April 29, 2026. In May 2026, the company closed a $36.5 million debt-and-equity financing: Avenue Capital Group is providing up to $25 million through a senior credit facility (with $10 million drawn initially), alongside approximately $11.5 million from warrant exercises. Proceeds are earmarked for sales force expansion, market access infrastructure, medical affairs, and manufacturing supply chain.

Key Personnel

Leonard L. Mazur serves as Chairman, CEO, and President. Mazur co-founded Citius Pharmaceuticals and has driven the oncology spinout strategy since LYMPHIR's FDA approval, bringing direct commercial-stage leadership experience from the parent organization. Detailed credentials for other C-suite members, including any Chief Medical or Chief Financial Officer, have not been publicly disclosed in available materials, reflecting the company's lean structure and reliance on shared services with Citius Pharma.

Strategic Partnerships

Avenue Capital Group is the company's principal financial partner, providing up to $25 million through a senior secured credit facility executed in May 2026. Uniphar, the Irish-headquartered healthcare services group, serves as Citius Oncology's European distribution partner for LYMPHIR, with initial product shipments confirmed in April 2026. The company also leverages investigator-sponsored relationships with the University of Minnesota and UPMC to generate expansion data at external cost, a capital-efficient approach for a single-asset commercial-stage company.

FAQ Section

Denileukin diftitox is a known mechanism — the original Ontak was approved in 1999 — but Citius's reformulated cxdl version addresses the manufacturing and tolerability limitations that constrained its predecessor's commercial life. The real strategic question is whether near-100% payer coverage and 83% formulary penetration in the first six months of launch translate into durable revenue growth, and whether the investigator-led expansion data are compelling enough to justify company-funded Phase II or III trials in larger indications.

CD25 (the high-affinity IL-2 receptor alpha chain) is overexpressed not only on malignant T-cells in CTCL but also on regulatory T-cells (Tregs), which suppress anti-tumor immunity across many cancer types. Depleting Tregs before CAR-T infusion — the rationale behind the University of Minnesota DLBCL study — could improve CAR-T engraftment in an immunosuppressed tumor microenvironment. The combination with pembrolizumab in solid tumors follows the same logic: removing an immunosuppressive brake before unleashing checkpoint-targeted effector activity.

The cxdl suffix denotes a proprietary manufacturing process that produces a more stable, higher-purity fusion protein than the original Ontak formulation. Ontak's commercial life was curtailed partly by an unpredictable side-effect profile linked to impurities and protein aggregation; a cleaner manufacturing profile should improve tolerability and physician confidence. That distinction is critical for payer negotiations and for building the formulary penetration the company has reported in its early launch data.

LYMPHIR launched in the US in December 2025 and reported $1.7 million in net revenue in its first full quarter (Q2 fiscal 2026), stepping up to $5.6 million across the first half of fiscal 2026 at approximately 80% gross margin. Payer coverage is near-complete and 83% of target accounts are on formulary or in active review — both ahead of where many rare-disease launches sit at six months. European distribution via Uniphar launched in April 2026, adding a second revenue geography, though volumes there are early.

The approved base is in cutaneous T-cell lymphoma, a rare hematologic malignancy of the skin. Expansion studies point toward broader hematologic malignancies — specifically DLBCL via the CAR-T preconditioning angle — and toward solid tumors through the pembrolizumab combination study completed at UPMC. The pipeline logic is coherent: CD25/IL-2 receptor biology spans T-cell-driven malignancies and immune regulation across tumor types, so the mechanism has plausible utility well beyond CTCL.

Citius Oncology is commercially staged with one approved, revenue-generating product and two programs generating investigator-sponsored data. The immediate milestones are accelerating US revenue growth from the LYMPHIR launch, converting the Uniphar European partnership into measurable sales, and deciding — based on the University of Minnesota and UPMC topline data — whether to initiate company-sponsored expansion trials in DLBCL or solid tumors. The $36.5 million May 2026 financing extends the commercial runway, but a move into formal Phase II expansion would require additional capital.

The company is at an early but pivotal commercial inflection point. Key items to track include:

Want to Update your Company's Profile?